GlaxoSmithKline and Pfizer announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination in adolescents and young adults aged 16–23.
The Category B recommendation by the ACIP states that vaccine decisions should be made by healthcare professionals based on individual patient risk. The ACIP also voted to include meningococcal group B vaccines in the CDC’s Vaccines for Children program for ages 16–18; in February 2015 the Committee voted to recommend serogroup B meningococcal vaccination for individuals ≥10 years of age at increased risk for meningococcal disease.
The ACIP recommendations will be sent to the director of the CDC and the U.S. Department of Health and Human Services for review and approval. Currently Bexsero (GlaxoSmithKline) and Trumenba (Pfizer) are approved by the Food and Drug Administration (FDA) for meningococcal group B vaccination in individuals aged 10–25.